Roche Enters $2.3 Billion Blood-Cancer Drug Deal With Nurix Therapeutics

交易核心条款 - 瑞士制药公司罗氏将向Nurix支付7亿美元的首付款 [1] - 双方将按60:40的比例分摊后续开发成本,其中罗氏承担较大份额 [1]

Roche Enters $2.3 Billion Blood-Cancer Drug Deal With Nurix Therapeutics - Reportify